Effects of a Novel Potent Aldose Reductase Inhibitor, GP : 1447, on Aldose Reductase Activity In Vitro and on Diabetic Neuropathy and Cataract Formation in Rats
スポンサーリンク
概要
- 論文の詳細を見る
GP-1447 {3-[(4, 5, 7-trifluorobenzothiazol-2-yl)methyl]-5-methylphenylacetic acid}, a novel aldose reductase (AR)inhibitor, exhibited highly potent and specific inhibition of AR activity from human placenta, human muscle, porcine and rat lens with IC<SUB>50</SUB> values ranging from 3 to 10 nM. Lineweaver-Burk plots revealed non-competitive inhibition between DL-glyceraldehyde or β-NADPH and inhibition of AR by GP-1447. In contrast to epalrestat, AR activity inhibited by GP-1447 did not recover after dialysis for 24 hr. Administration of GP-1447 to streptozotocin (STZ)-induced diabetic rats for 5 days beginning 1 week after STZ injection effectively inhibited the accumulation of sorbitol in the sciatic nerve, lens and retina with ED<SUB>50</SUB> values of 0.25, 1.6 and 2.9 mg/kg/day, respectively. The motor nerve conduction velocity (MCV)in STZ-induced diabetic rats was significantly decreased 4 weeks after the induction of diabetes. Treatment with GP-1447 for the following 2 weeks dose-dependently restored the decreased MCV with an ED<SUB>50</SUB> value of 0.28 mg/kg/day. Administration of GP-1447 (3 and 15 mg/kg/day for 12 weeks beginning 3 days after STZ injection)completely prevented cataract formation and was accompanied by marked inhibition of sorbitol accumulation in the lens. Furthermore, partial reversibility of cataract formation and morphological changes of the lens was observed in diabetic rats treated with 15 mg/kg/day of GP-1447 for 5 weeks beginning 8 weeks after the induction of diabetes. From these results, GP-1447 would be expected to exert potent ameliorating effects on some diabetic complications. Potent inhibition of cataract formation will be one of the characteristics of this compound.
- 社団法人 日本薬理学会の論文
- 1997-02-01
著者
-
Matsuura Akihiro
Pharmaceutical Research Laboratories, Sapporo Breweries Ltd.
-
Ashizawa Naoki
Pharmaceutical Research Laboratories Research Center Research And Development Division Grelan Pharma
-
Aotsuka Tomoji
Pharmaceutical Research Laboratories Research Center Research And Development Division Grelan Pharma
-
YOSHIDA Motoyuki
Pharmaceutical Research Laboratories, Research Center, Research and Development Division, Grelan Pha
-
SUGIYAMA Yoshiko
Pharmaceutical Research Laboratories, Research Center, Research and Development Division, Grelan Pha
-
AKAIKE Nobuhide
Pharmaceutical Research Laboratories, Research Center, Research and Development Division, Grelan Pha
-
OHBAYASHI Shigeo
Pharmaceutical Research Laboratories, Research Center, Research and Development Division, Grelan Pha
-
ABE Naoki
Pharmaceutical Research Laboratories, Research Center, Research and Development Division, Grelan Pha
-
FUKUSHIMA Kanako
Pharmaceutical Research Laboratories, Research Center, Research and Development Division, Grelan Pha
-
Matsuura Akihiro
Pharmaceutical Research Laboratories Research Center Research And Development Division Grelan Pharma
-
Akaike Nobuhide
Pharmaceutical Research Laboratories Research Center Research And Development Division Grelan Pharma
-
Fukushima Kanako
Pharmaceutical Research Laboratories Research Center Research And Development Division Grelan Pharma
-
Sugiyama Yoshiko
Pharmaceutical Research Laboratories Research Center Research And Development Division Grelan Pharma
-
Ohbayashi Shigeo
Pharmaceutical Research Laboratories Research Center Research And Development Division Grelan Pharma
-
Yoshida Motoyuki
Pharmaceutical Research Laboratories, Research Center, Research and Development Division, Grelan Pharmaceutical Co., Ltd.
関連論文
- Aspergillomarasmine A and B, Potent Microbial Inhibitors of Endothelin-converting Enzyme
- Effects of a Novel Potent Aldose Reductase Inhibitor, GP : 1447, on Aldose Reductase Activity In Vitro and on Diabetic Neuropathy and Cataract Formation in Rats
- Pharmacological Profiles of Aspergillomarasmines as Endothelin Converting Enzyme Inhibitors.
- Pharmacological Profiles of a Novel Aldose Reductase Inhibitor, SPR-210, and Its Effects on Streptozotocin-Induced Diabetic Rats.